Necitumumab: new treatment for advanced squamous non-small cell lung cancer

Portrazza (necitumumab) in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing, squamous, non-small cell lung cancer (NSCLC) in patients who have not received prior chemotherapy for this condition.

Activation of EGFR has been linked to malignant progression, induction of angiogenesis and inhibition of apoptosis, or cell death. | SCIENCE PHOTO LIBRARY
Activation of EGFR has been linked to malignant progression, induction of angiogenesis and inhibition of apoptosis, or cell death. | SCIENCE PHOTO LIBRARY

Necitumumab is a recombinant human IgG1 monoclonal antibody that binds with high affinity and specificity to EGFR-1. It blocks the ligand binding site, preventing activation of the receptor by all known ligands.

A multicentre phase III study evaluated the efficacy of necitumumab in 1093 patients with stage IV squamous NSCLC.

Further information
View Portrazza drug record
Summary of Product Characteristics
Manufacturer: Lilly

Patients were randomised to receive necitumumab in combination with gemcitabine and cisplatin (n=545) or gemcitabine and cisplatin chemotherapy alone (n=548).

Overall survival rate

Necitumumab plus gemcitabine and cisplatin produced a significantly longer median overall survival rate (primary efficacy endpoint) of approximately 11.5 months (95% CI 10.4–12.6) compared with 9.9 months (95% CI 8.9–11.1) for patients receiving gemcitabine and cisplatin (p=0.01)

Safety

The most common adverse events were skin reactions, venous thromboembolic events and laboratory abnormalities. The safety profile of the triple combination therapy was found to be acceptable and in line with expectations.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases